Consideration on core requirements for RMPs of COVID-19 vaccines
Consideration on core requirements for RMPs of COVID-19 vaccines
Consideration on core requirements for RMPs of COVID-19 vaccines
Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 12/12/2018, Revision: 7, Status: Withdrawn
Agenda - HMA/EMA Annual Data Forum 2025
Antiviral medicines for pandemic influenza
Veterinary signal assessment report for marketing authorisation holders
Human medicines European public assessment report (EPAR): Tuzodi, midazolam, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Hetlioz, tasimelteon, Date of authorisation: 03/07/2015, Revision: 9, Status: Authorised
Veterinary Scientific Advice procedure – timelines 2026 - information for applicants
Dengvaxia : EPAR - All authorised presentations
Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - November 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2025, 11:00 (CET) to 18 November 2025, 12:00 (CET)